Inhibitory Effects of Triptolide on Human Liver Cytochrome P450 Enzymes and P-Glycoprotein

Overview

Journal Eur J Drug Metab Pharmacokinet

Date 2016 Feb 15

PMID 26874845

Citations 19

Authors

Hanhua Zhang

Guangkui Ya

Hongbing Rui

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: Triptolide is an active component derived from Tripterygium wilfordii and it possesses numerous pharmacological activities. However, it remains unclear how triptolide influences the activity of human liver cytochrome P450 (CYP) enzymes and P-glycoprotein (P-gp).

Methods: In this study, the inhibitory effects of triptolide on the eight human liver CYP isoforms (i.e., 1A2, 3A4, 2A6, 2E1, 2D6, 2C9, 2C19, and 2C8) were investigated in vitro using human liver microsomes (HLMs), and the effects of triptolide on the activity of P-gp were investigated using a rhodamine-123 uptake assay.

Results: The results showed that triptolide inhibited the activity of CYP1A2 and CYP3A4, with 50 % inhibitory concentration (IC) values of 14.18 and 8.36 μM, respectively, but that other CYP isoforms were not affected. Enzyme kinetic studies showed that triptolide was not only a non-competitive inhibitor of CYP1A2, but also a competitive inhibitor of CYP3A4, with inhibition constant (K ) values of 7.32 and 5.67 μM, respectively. In addition, triptolide is a time-dependent inhibitor for CYP1A2, and the concentration at 50 % maximum inactivation (K ) and maximum inactivation (K ) values were 286.5 μM and 0.024 min, respectively. The rhodamine-123 uptake assay showed that triptolide could not affect the activity of P-gp.

Conclusions: The in vitro studies of triptolide with CYP isoforms and P-gp indicate that triptolide has the potential to cause pharmacokinetic drug interactions with other co-administered drugs metabolized by CYP1A2 and CYP3A4. Further clinical studies are needed to evaluate the significance of this interaction.

Citing Articles

Pharmacological, computational, and mechanistic insights into triptolide's role in targeting drug-resistant cancers.

Hussain M, Mujwar S, Babu M, Goyal K, Chellappan D, Negi P Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39862263 DOI: 10.1007/s00210-025-03809-5.

Genotoxicity of pyrrolizidine alkaloids in metabolically inactive human cervical cancer HeLa cells co-cultured with human hepatoma HepG2 cells.

Hadi N, Bankoglu E, Stopper H Arch Toxicol. 2022; 97(1):295-306.

PMID: 36273350 PMC: 9816206. DOI: 10.1007/s00204-022-03394-z.

The molecular pathogenesis of triptolide-induced hepatotoxicity.

Hu Y, Wu Q, Wang Y, Zhang H, Liu X, Zhou H Front Pharmacol. 2022; 13:979307.

PMID: 36091841 PMC: 9449346. DOI: 10.3389/fphar.2022.979307.

study on the effect of peucedanol on the activity of cytochrome P450 enzymes.

Zhang C, Li Y, Yin C, Zheng J, Liu G Pharm Biol. 2022; 59(1):935-940.

PMID: 35294326 PMC: 8274509. DOI: 10.1080/13880209.2021.1944223.

Investigation of the effect of verapamil on the regional absorption of sofosbuvir from rabbit intestine in situ.

Mohsen N, El-Din E, Osman M, Ashmawy S Daru. 2022; 30(1):49-58.

PMID: 35023081 PMC: 9114277. DOI: 10.1007/s40199-021-00429-1.

References

Nabekura T, Yamaki T, Kitagawa S . Effects of chemopreventive citrus phytochemicals on human P-glycoprotein and multidrug resistance protein 1. Eur J Pharmacol. 2008; 600(1-3):45-9. DOI: 10.1016/j.ejphar.2008.10.025. View

Nguyen M, Staubach P, Wolffram S, Langguth P . Effect of single-dose and short-term administration of quercetin on the pharmacokinetics of talinolol in humans - Implications for the evaluation of transporter-mediated flavonoid-drug interactions. Eur J Pharm Sci. 2014; 61:54-60. DOI: 10.1016/j.ejps.2014.01.003. View

Wang B, Zhou S . Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009; 16(31):4066-218. DOI: 10.2174/092986709789378198. View

Pandit S, Mukherjee P, Ponnusankar S, Venkatesh M, Srikanth N . Metabolism mediated interaction of α-asarone and Acorus calamus with CYP3A4 and CYP2D6. Fitoterapia. 2010; 82(3):369-74. DOI: 10.1016/j.fitote.2010.11.009. View

Jeong H, Kong T, Kwon S, Hong S, Yeon S, Choi J . Effect of honokiol on cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in human liver microsomes. Molecules. 2013; 18(9):10681-93. PMC: 6269737. DOI: 10.3390/molecules180910681. View

Shao F, Wang G, Xie H, Zhu X, Sun J, A J . Pharmacokinetic study of triptolide, a constituent of immunosuppressive chinese herb medicine, in rats. Biol Pharm Bull. 2007; 30(4):702-7. DOI: 10.1248/bpb.30.702. View

Grzegorzewska A, Frankiewicz D, Breborowicz D, Matlawska I, Bylka W . Disseminated cutaneous Kaposi sarcoma in a patient receiving triptolide/tripdiolide for rheumatoid arthritis. Med Sci Monit. 2012; 18(8):CS67-71. PMC: 3560695. DOI: 10.12659/msm.883256. View

Liu T, Qian G, Wang W, Zhang Y . Molecular docking to understand the metabolic behavior of GNF-351 by CYP3A4 and its potential drug-drug interaction with ketoconazole. Eur J Drug Metab Pharmacokinet. 2014; 40(2):235-8. DOI: 10.1007/s13318-014-0201-1. View

Li X, Jiang Z, Zhang L . Triptolide: progress on research in pharmacodynamics and toxicology. J Ethnopharmacol. 2014; 155(1):67-79. DOI: 10.1016/j.jep.2014.06.006. View

10.

Shimada T, Mimura M, Inoue K, Nakamura S, Oda H, Ohmori S . Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans. Arch Toxicol. 1997; 71(6):401-8. DOI: 10.1007/s002040050403. View

11.

Chen Z, Sangwan V, Banerjee S, Chugh R, Dudeja V, Vickers S . Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the death receptor pathway. Cancer Lett. 2014; 348(1-2):156-66. PMC: 4028717. DOI: 10.1016/j.canlet.2014.03.016. View

12.

Qi X, Liang S, Ge G, Liu Y, Dong P, Zhang J . Inhibitory effects of sanguinarine on human liver cytochrome P450 enzymes. Food Chem Toxicol. 2013; 56:392-7. DOI: 10.1016/j.fct.2013.02.054. View

13.

Unger M . Pharmacokinetic drug interactions involving Ginkgo biloba. Drug Metab Rev. 2013; 45(3):353-85. DOI: 10.3109/03602532.2013.815200. View

14.

Park B . Triptolide, a diterpene, inhibits osteoclastogenesis, induced by RANKL signaling and human cancer cells. Biochimie. 2014; 105:129-36. DOI: 10.1016/j.biochi.2014.07.003. View

15.

Wrighton S, Stevens J . The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol. 1992; 22(1):1-21. DOI: 10.3109/10408449209145319. View

16.

Hu X, Huang W, Yang Y . Cytochrome P450 isoenzymes in rat and human liver microsomes associate with the metabolism of total coumarins in Fructus Cnidii. Eur J Drug Metab Pharmacokinet. 2014; 40(4):373-7. DOI: 10.1007/s13318-014-0219-4. View

17.

Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y, Sugiyama Y . Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu Rev Pharmacol Toxicol. 1998; 38:461-99. DOI: 10.1146/annurev.pharmtox.38.1.461. View

18.

Li W, Liu Y, He Y, Zhang J, Gao Y, Ge G . Characterization of triptolide hydroxylation by cytochrome P450 in human and rat liver microsomes. Xenobiotica. 2008; 38(12):1551-65. DOI: 10.1080/00498250802503359. View

19.

Binkhathlan Z, Lavasanifar A . P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. Curr Cancer Drug Targets. 2013; 13(3):326-46. DOI: 10.2174/15680096113139990076. View

20.

Lee S, Lee J, Kang W, Kwon K, Park S, Oh S . Cytochrome P450-mediated herb-drug interaction potential of Galgeun-tang. Food Chem Toxicol. 2012; 51:343-9. DOI: 10.1016/j.fct.2012.10.012. View